NCT01825330已完成不适用
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Neuronix Ltd
- 入组人数
- 131
- 试验地点
- 18
- 主要终点
- Efficacy
研究概览
简要总结
The study tests the effect of the NeuroAD on Alzheimer patients' cognitive function. The NeuroAD uses non-invasive stimulation of both magnetic and cognitive training.
详细描述
The NeuroAD system is a combined system of Transcranial Magnetic Stimulation and cognitive training and is a non-invasive therapeutic system for the improvement of Alzheimer patients' cognitive function.
A potential participant will undergo screening procedures to confirm eligibility to participate in the study, followed by randomization procedure to one of the study groups - treatment or sham (placebo) Patient will attend the clinic 5 times a week for 6 weeks, approximately an hour every day for treatment/sham. The patient will be required to return to the clinic for follow-up.
Up to 150 patients will be enrolled in up to 10 clinical sites in the US and Israel.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 60 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female age 60-90 years
- •Patients diagnosed with mild or moderate stage of Alzheimer's Disease, according to the DSM-IV criteria.
- •MMSE score 18 to 26
- •ADAS-Cog above 17
- •Physical clearance for study participation as evaluated by the clinician.
- •Spouse, family member or professional caregiver agree and capable of taking care and be responsible for the participation of the patient in the study (answering questions regarding the patient's condition and assuming responsibility for medication)
- •Agreement to participate in approximately 14 weeks during the study.
- •Normal to near-normal vision and hearing with correction as needed (e.g. corrective lenses, hearing aid).
- •Fluent in English or Hebrew
- •Minimum of 8th grade education
- •If medicated for AD, then use of cholinesterase inhibitors, memantine or Ginko-biloba for at least 3 months and on stable dose for at least 60 days prior to screening.
排除标准
- •CDR 0, 0.5 or 3
- •Severe agitation
- •Mental retardation
- •Patient lacking capacity to consent to study participation
- •Unstable medical condition
- •Use of benzodiazepines or barbiturates 2 weeks prior to screening
- •Pharmacological immunosuppression
- •Participation in a clinical trial with any investigational agent within 6 months prior to study enrollment
- •History of Epileptic Seizures or Epilepsy
- •Contraindication for performing MRI scanning
- •Contraindication for receiving TMS treatment according to a TMS questionnaire
- •Pregnant women and women who have the ability to become pregnant unless they are on an acceptable method of contraception during the study.
- •Patients with depression, bipolar disorder or psychotic disorders or any other neurological or psychiatric condition (whether now or in the past), which the Investigator finds as interfering with the study
- •Alcoholism or drug addiction as defined by DSM-IV within last 5 years (addicted more than one year and or in remission less than 3 years) or severe sleep deprivation
- •Patients with metal implants in the head, (i.e. cochlear implants, implanted brain stimulators, aneurysm clips) with the exception of metal implants in mouth
- •Patients with personal history of either any clinically defined medical disorder (which the investigator finds as interfering with the study) or any clinically defined neurological/psychiatric disorder (other than AD), including (but not limited to): epilepsy, stroke, brain lesions, substance abuse, vitamin B12 deficiency, abnormal thyroid function, cerebrovascular condition, other neurodegenerative disease, head trauma, multiple sclerosis; or personal history of previous neurosurgery or head trauma that resulted in loss of consciousness.
- •Patients with any signs or symptoms of increased intracranial pressure, as determined in a neurological exam.
- •Cardiac pacemakers
- •Implanted medication pumps
- •Intracardiac lines
- •Significant heart disease
- •Currently taking medication that lower the seizure threshold.
- •Patients on which TMS Motor Threshold cannot be found.
- •Patient underwent TMS treatment in the past.
结局指标
主要结局
Efficacy
时间窗: 7 weeks
Change from Baseline to week 7 in ADAS-Cog score. ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive
次要结局
- Efficacy(12 weeks)
研究者
研究点 (18)
Loading locations...
相似试验
招募中
不适用
Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's DementiaDementiaAlzheimer's DiseaseBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurodegenerative DiseasesNeurocognitive DisordersMental DisorderNCT06088121Advanced Technology & Communications180
已完成
不适用
Effects of Transcranial Magnetic Stimulation (TMS) and Cognitive Training for Alzheimer PatientsAlzheimer Disease, Early OnsetNCT00909285Assaf-Harofeh Medical Center20
已完成
不适用
Effect of NeuroAD on Alzheimer PatientsAlzheimer's DiseaseNCT01825317Neuronix Ltd32
终止
不适用
TMS in Preclinical and Prodromal AD: Modulation of Brain Networks and MemoryAlzheimer DiseaseMild Cognitive ImpairmentAgingNCT04294888Massachusetts General Hospital4
招募中
早期 1 期
Transcranial Magnetic Stimulation Treatment for Alzheimer's DiseaseAlzheimer DiseaseMild Cognitive ImpairmentLogopenic Progressive AphasiaAmnestic SymptomsNCT06538311Massachusetts General Hospital30